Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lupin’s Karkaria On Biosimilars Pushback And Interchangeability

Questions Need For Separate Studies

Executive Summary

Lupin's biotech president notes push-back by innovator firms against biosimilars in the US parallels that witnessed when small molecule generic competition first emerged, but remains confident that biosimilars will gain traction. The executive also sees little need for separate interchangeability studies.

 

You may also be interested in...



India 2019 – R&D Highs, Compliance Woes And Other Lows

2019 saw Indian companies advance innovation efforts and build and expand their specialty portfolios and biosimilars businesses. But manufacturing compliance issues weighed down several firms while on another front charges against the Singh brothers of Ranbaxy escalated.

India 2019 – R&D Highs, Compliance Woes And Other Lows

2019 saw Indian companies advance innovation efforts and build and expand their specialty portfolios and biosimilars businesses. But manufacturing compliance issues weighed down several firms while on another front charges against the Singh brothers of Ranbaxy escalated.

German Doctors Fear ‘Nocebo’ Impact From Substitution

Switching German patients from one biologic to another without involving their doctor could cause patients to perceive biosimilars as having inferior safety and efficacy, a local physicians’ body is warning. 

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC141237

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel